Skip to content

Public FDA record

Z-1289-2021: BARD MARQUEE Disposable Core Biopsy Instruments XX.Xcm, XX.Xcm, XXg x XXcm REF XXXXXXX Note - for defin

Recall record Z-1289-2021 for Bard Peripheral Vascular Inc. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-1289-2021
Company in FDA record
Bard Peripheral Vascular Inc
FDA record creation date
Mar 22, 2021
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

Due to the Penetration Depth Switch used to select the desired penetration depth of the biopsy needle for soft tissue biopsies, detaches from the device during use.

Source facts

Action
On 02/11/2021, the firm sent an "UGENT MEDICAL DEVICE RECALL" Notification Letter via FedEx or email to customers/distributors informing them that the Recalling Firm has received reports that the Penetration Depth Switch used to select the desired penetration depth of the biopsy needle for soft tissue biopsies, detaches from the device during use and may results in (1) prolongation of the biopsy procedures as the user obtains a replacement device, (2) undershooting the lesion unsuspectedly, compromising the sample quality and potentially leading to a misdiagnosis (3) or if the penetration is overshot, the device may pierce adjacent tissue and/or organs causing injury. Customers are instructed to: 1. Check all inventory locations within their institution for the catalog/lot number combination listed in this recall notice and destroy all affected product remaining in their possession. 2. Share the recall notice with any users of the product, within their facilities, to ensure they are also aware of this recall. 3. If purchased this product from a distributor, contact the distributor for further instructions. 4. Complete and return the attached Customer Response Form to the Recalling Firm's contact noted on the form confirming acknowledgement of the recall notification, whether or not they have any affected product, so that Recalling Firm may acknowledge the receipt of the notification and process any applicable replacement orders. 5. Report any adverse health consequences experienced with the use of this product to the Recalling Firm. Actions to be taken by the Recalling Firm: 1. The firm will process replacement orders for all customers affected by the recall following receipt of the completed Customer Response Form. 2. Depending on the specific product code, there may be delays in the fulfillment of replacement orders. the firm understands that supply interruptions can impact our customers ability to provide the best care for their patients and takes t
Initiated
2021-01-14
Root cause
Process control
Terminated
2025-01-28
Distribution
U.S.: AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, Puerto Rico, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV, and WY O.U.S.: Australia, Belgium, Canada, Europe, India, and Singapore
Recall number
Z-1289-2021
Recall status
Terminated
CDRH record ID
185802
FDA record created
2021-03-22
Recall event number
87316

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗